Back to top
more

Takeda Pharmaceutical Co. (TAK)

(Delayed Data from NYSE)

$15.08 USD

15.08
2,564,957

+0.20 (1.34%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $15.07 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Panel Of Zacks Experts headshot

How Do Earnings Impact The Stock Market?

Q2 Earnings Season is in full swing and Sheraz Mian joins the show to discuss everything you need to know!

Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates

Seattle Genetics (SGEN) betters loss estimates and rides high on revenue beat in Q2.

J&J Submits BLA for Subcutaneous Formulation of Darzalex

Johnson & Johnson (JNJ) submits a BLA to the FDA, seeking approval for a subcutaneous formulation of its multiple myeloma drug.

Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status

The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.

J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma

Johnson & Johnson's (JNJ) label expansion application, seeking approval for Darzalex+Revlimid to treat transplant ineligible newly diagnosed patients with multiple myeloma, receives FDA approval.

AbbVie Announces Lifting of FDA's Partial Hold on CANOVA Study

AbbVie (ABBV) receives encouraging news as FDA lifts partial clinical hold on a late-stage study evaluating Venclexta in relapsed/refractory multiple myeloma.

Verastem Up on Positive Data From Early-Stage Copiktra Study

Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.

Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?

Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.

Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y

Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.

What's in the Cards for Sunesis (SNSS) This Earnings Season?

Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.

Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark

Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.

Top Ranked Income Stocks to Buy for April 25th

Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 25th

Kamada to Begin Phase III Study for Inhaled AAT Product in 2H

Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.

Takeda Pharmaceutical Enters Oversold Territory

Takeda Pharmaceutical Company Limited (TAK) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Will Ironwood Suffer From Dependence on Linzess' Progress?

Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.

Moving Average Crossover Alert: Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (TAK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Company News For Mar 5, 2019

Companies in the news are; PLCE, BIIB, NITE, ASND and TAK

Swarup Gupta headshot

5 Tiny Biotech Stocks With Superb Growth Potential

A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.

Ironwood to Get New CEO, Current CEO to Head Latest Spinoff

Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.